About Alchemab
Alchemab is a company based in London (United Kingdom) founded in 2019. Alchemab has raised $148.66 million across 6 funding rounds from investors including Lilly, Gov.uk and RA Capital. The company has 8 employees as of December 31, 2020. Alchemab offers products and services including Antibody Therapeutics. Alchemab operates in a competitive market with competitors including T3D Therapeutics, Pardes Biosciences, Alzheon, Longeveron and Vaxxinity, among others.
- Headquarter London, United Kingdom
- Employees 8 as on 31 Dec, 2020
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Alchemab Therapeutics Ltd
- Date of Incorporation 14 Aug, 2019
- Jurisdiction LONDON, UNITED KINGDOM
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$148.66 M (USD)
in 6 rounds
-
Latest Funding Round
$34 M (USD), Series A
Jul 09, 2026
-
Investors
Lilly
& 9 more
-
Employee Count
8
as on Dec 31, 2020
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Alchemab
Alchemab offers a comprehensive portfolio of products and services, including Antibody Therapeutics.
Develops treatments from resilient individuals' antibodies for hard-to-treat diseases.
People of Alchemab
Unlock access to complete
Unlock access to complete
Funding Insights of Alchemab
Alchemab has successfully raised a total of $148.66M across 6 strategic funding rounds. The most recent funding activity was a Series A round of $34 million completed in July 2026. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Alchemab
Alchemab has secured backing from 10 investors, including institutional and venture fund investors. Prominent investors backing the company include Lilly, Gov.uk and RA Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital fund focused on early-stage healthcare startups
|
Locked | Locked | Locked | |
|
Venture capital fund and fund of funds focused on the life science sector
|
Locked | Locked | Locked | |
|
Venture capital firm focused on multiple sectors
|
Locked | Locked | Locked |
Investor details for Alchemab
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Alchemab
Investment portfolio details for Alchemab
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Alchemab
Detailed financials for Alchemab
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Alchemab Comparisons
Peer comparison for Alchemab
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Alchemab
Alchemab operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as T3D Therapeutics, Pardes Biosciences, Alzheon, Longeveron and Vaxxinity, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Therapeutics for neurodegenerative diseases, including Alzheimer's, are developed.
|
|
| Locked | Locked | Locked |
Therapeutics for pandemic diseases including SARS-CoV-2 are developed.
|
|
| Locked | Locked | Locked |
Oral inhibitors of amyloid aggregation for Alzheimer's treatment are developed.
|
|
| Locked | Locked | Locked |
Cellular therapies for aging-related and life-threatening conditions are developed.
|
|
| Locked | Locked | Locked |
Vaccines for neurological disorders and infectious diseases are developed.
|
|
| Locked | Locked | Locked |
Provider of antibody-based therapies to monitor viral infections
|
Detailed competitors of Alchemab
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Alchemab
Complete news archive for Alchemab
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Alchemab
Alchemab was founded in 2019.
Alchemab is headquartered in London, United Kingdom. It is registered at London, England, United Kingdom.
Alchemab is a funded company, having raised a total of $148.66M across 6 funding rounds to date.
As of Dec 31, 2020, the latest employee count at Alchemab is 8.
Developer of antibody-based therapeutics to treat cancers, neurodegenerative conditions, and infectious diseases. The company is developing novel antibody therapeutic candidates by understanding the binding targets of the antibodies and replicating the action.
Alchemab's top competitors include NRx, ExeVir Bio and Alzheon.
Alchemab offers Antibody Therapeutics.
Alchemab has 10 investors. Key investors include Lilly, Gov.uk, RA Capital, Innovate UK, and SV Health Investors.